- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07947498
Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction (MI-Holter)
Evaluation of the Prognostic Value of Long-term(2 Weeks) Electrocardiogram Analysis After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
This single-center, single-group study will evaluate the prognostic value of long-term electrocardiographic monitoring in adults with acute myocardial infarction who undergo primary percutaneous coronary intervention. After written informed consent, eligible participants will have a MEMO Patch2 long-term Holter monitor applied on the day of, or the day after, the procedure and will wear it for 2 weeks. The study will classify high-risk arrhythmias detected during monitoring and compare long-term clinical outcomes according to arrhythmia classification.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Patients presenting with acute myocardial infarction and undergoing primary percutaneous coronary intervention will be screened at Chungnam National University Hospital. Eligible adults who understand the study and provide written informed consent will be enrolled.
A MEMO Patch2 long-term Holter monitor will be attached on the day of, or the day after, the procedure. Participants will wear the device for 2 weeks and have it removed at an outpatient visit, after which the electrocardiographic recordings will be analyzed. Recorded arrhythmias include ventricular tachycardia, ventricular fibrillation, nonsustained ventricular tachycardia, atrial fibrillation, atrial flutter, high-degree atrioventricular block, and ventricular premature complexes.
The primary objective is to classify high-risk arrhythmias detected by 2-week monitoring. The secondary objective is to compare long-term prognosis according to arrhythmia classification, including all-cause death, cardiac death, noncardiac death, rehospitalization for heart failure, recurrent myocardial infarction, and stroke. Baseline diseases, laboratory results, social history, coronary intervention findings, prescribed medications, height, weight, and body mass index will also be collected. Statistical analyses described in the Protocol include descriptive statistics, t-tests, chi-square tests, Pearson correlation, multiple regression, multiple Cox regression, and Kaplan-Meier survival analysis, with a two-sided significance level of p<0.05.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: JunHyung Kim
- Telefoonnummer: +82-042-280-8237
- E-mail: william@cnu.ac.kr
Studie Locaties
-
-
-
Daejeon, Zuid -Korea, 35015
- Werving
- Chungnam National University Hospital
-
Contact:
- JunHyung Kim
- Telefoonnummer: +82-042-280-8237
- E-mail: william@cnu.ac.kr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adult aged 20 years or older.
- Diagnosed with STEMI and underwent primary percutaneous coronary intervention; or diagnosed with NSTEMI, underwent primary percutaneous coronary intervention, and meets at least one of the following conditions: (a) left ventricular ejection fraction ≤45% on echocardiography; (b) ventricular tachycardia, ventricular fibrillation, atrial fibrillation, or high-degree atrioventricular block during or after percutaneous coronary intervention (ventricular tachycardia is defined as ≥3 consecutive ventricular premature complexes); or (c) post-procedural TIMI flow grade 0-2 during percutaneous coronary intervention.
- Has received and understood an explanation of the study and signed the informed consent form.
Exclusion Criteria:
- Refuses to participate in the study.
- Is transferred to another hospital immediately after the procedure and cannot be followed.
- Is unable to express an intention to participate in the study, such as due to unconsciousness.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: MEMO Patch2 Long-Term Holter Monitoring
Participants with acute myocardial infarction who undergo primary percutaneous coronary intervention will have a MEMO Patch2 long-term Holter monitor attached on the day of, or the day after, the procedure. The device will be worn continuously for 2 weeks and removed at an outpatient visit. Recorded arrhythmias will be analyzed, and long-term prognosis will be compared according to arrhythmia classification. |
MEMO Patch2 is a detachable long-term Holter monitoring device. It will be applied on the day of, or the day after, primary percutaneous coronary intervention and worn for 2 weeks to record arrhythmias that may be missed by in-hospital monitoring. It will be removed at an outpatient visit, and the recordings will then be analyzed.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Classification of High-Risk Arrhythmias
Tijdsspanne: At the outpatient visit after completion of the 2-week MEMO Patch2 monitoring period
|
High-risk arrhythmias detected by MEMO Patch2 will be classified. Arrhythmias assessed include ventricular tachycardia, ventricular fibrillation, nonsustained ventricular tachycardia, atrial fibrillation, atrial flutter, high-degree atrioventricular block, and ventricular premature complexes. |
At the outpatient visit after completion of the 2-week MEMO Patch2 monitoring period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Long-Term Prognosis According to Arrhythmia Classification
Tijdsspanne: Through study completion (anticipated 2026-12-31)
|
Long-term prognosis will be compared according to arrhythmia classification. Outcomes include all-cause death, cardiac death, noncardiac death, rehospitalization for heart failure, recurrent myocardial infarction, and stroke. |
Through study completion (anticipated 2026-12-31)
|
Medewerkers en onderzoekers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MI-Holter
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data collected in this study are not planned to be shared with external researchers. Any future sharing would require separate sponsor approval and compliance with applicable privacy, ethical, and institutional requirements.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .